The JAK/STAT Signaling Pathway: From Bench to Clinic
November 2021
in “
Signal Transduction and Targeted Therapy
”
TLDR The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
The document discusses the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, a crucial component in cellular processes like growth, differentiation, and immune response. Dysregulation of this pathway is linked to various cancers and autoimmune diseases. The pathway consists of ligand-receptor complexes, JAKs, and STATs, each with specific roles in biological processes. The document also explores the interaction between the JAK/STAT pathway and other pathways like TGFβ and MAPK. The JAK/STAT pathway is implicated in diseases like Hodgkin lymphoma, natural killer/T-cell lymphoma, myeloproliferative neoplasm, hepatocellular carcinoma, systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, Parkinson's disease, hair loss, and age-related diseases. JAK inhibitors have shown potential in treating these conditions. The document also discusses the effectiveness of JAK inhibitors in treating diseases such as rheumatoid arthritis, inflammatory bowel disease, alopecia areata, COVID-19, and atopic dermatitis. The potential of natural compounds in regulating immune responses is also discussed. Future research should focus on understanding the JAK/STAT pathway's mechanisms, maximizing treatment efficacy while minimizing adverse effects, and exploring predictive and prognostic biomarkers.